NCE-1 Intelligence & Market Opportunity

Zevtera

Ceftobiprole Medocaril Sodium

Antibiotic

Intravenous Powder Injection

Zevtera is an advanced-generation cephalosporin antibiotic for treating Staphylococcus aureus bacteremia, including right-sided endocarditis, skin infections, and pneumonia in both adults and children. It works by blocking bacterial cell wall synthesis and remains active against MRSA and resistant strains.

Approval Date

03-Apr-24

NCE-1 Date

03-Apr-28

NCE Date

03-Apr-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

1.9623

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

114

2032

133

Molecule profile

Details & specifications

Molecule

Ceftobiprole Medocaril Sodium

Innovator

BASILEA PHARMACEUTICA INTERNATIONAL LTD ALLSCHWIL

Dosage Form

Intravenous Powder Injection

Strength

667 mg/vial

Therapeutic Category

Antibiotic

Usage

To treat certain bloodstream infections, bacterial skin and associated tissue infections, and community-acquired bacterial pneumonia

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.